相关实验视频

Updated: Sep 14, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

在贝兰他马布暴露后复发性耐火性多发性骨髓瘤中,顺序性BCMA导向疗法的现实世界结果

Prerna Mewawalla¹, Rachel Dileo¹, Yue Yin²

¹Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA.

Clinical lymphoma, myeloma & leukemia

|July 18, 2025

概括

顺序B细胞成熟抗原 (BCMA) 疗法,如CAR T或双特异性抗体 (BsAb),在多发性骨髓瘤中可能在贝兰他马布马福多丁后可行. 然而,与以前没有BCMA暴露的患者相比,结果仍然较差.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

针对B细胞成熟抗原 (BCMA) 的疗法越来越多地用于多发性骨髓瘤.
用BCMA导向疗法的顺序治疗结果需要进一步调查.

研究的目的:

为了评估复发性/耐药性多发性骨髓瘤 (RRMM) 患者的现实世界结果,在治疗贝兰他马布 (belantamab mafodotin) 进展后使用BCMA导向疗法治疗.
在这个患者群体中,比较CAR T和双特异抗体 (BsAb) 疗法之间的结果.

主要方法:

对23名RRMM患者的多中心追溯分析.
在Belantamab mafodotin进展后,患者接受了CAR T或BsAb治疗.
评估了包括整体应答率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS) 在内的结果.

主要成果:

总体响应率 (ORR) 为65% (CAR T:79%,BsAb:44%). 这是一个很好的结果.
中位数PFS为5个月,中位数OS为28个月.
在CAR T和BsAb之间没有观察到PFS的显著差异,或者基于从贝兰他马布到BCMA治疗的时间.

结论:

针对BCMA的BsAb或CART对于RRMM患者在belantamab后是可行的.
与以前没有BCMA暴露的患者相比,结果较差.
治疗选择和自最后一次BCMA暴露以来的时间没有影响结果.

关键词:

抗体与药物的结合物.双特异性抗体双特异性抗体在CART-T中,我们可以使用CAR-T.外骨髓性疾病是外骨髓性疾病高风险的细胞遗传学

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...